Cited by 1,063Receptor Mechanisms and SignalingNeuroscience and Neuropharmacology ResearchNeurotransmitter Receptor Influence on Behavior

The DOI matches its Crossref record; 139 of the 139 references it cites were found in a registry or an index.

Allosteric modulators of GPCRs: a novel approach for the treatment of CNS disorders

Open access

Jeffrey Conn, P., Christopoulos, Arthur, Lindsley, Craig W.·2009·Nature Reviews Drug Discovery

DOI 10.1038/nrd2760PMC PMC2907734

Open this paper in CoChat — free account

Abstract

Despite G-protein-coupled receptors (GPCRs) being among the most fruitful targets for marketed drugs, intense discovery efforts for several GPCR subtypes have failed to deliver selective drug candidates. Historically, drug discovery programmes for GPCR ligands have been dominated by efforts to develop agonists and antagonists that act at orthosteric sites for endogenous ligands. However, in recent years, there have been tremendous advances in the discovery of novel ligands for GPCRs that act at allosteric sites to regulate receptor function. These compounds provide high selectivity, novel modes of efficacy and may lead to novel therapeutic agents for the treatment of multiple psychiatric and neurological human disorders.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1038/nrd2760

Cites

139 of 139 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Can the pharmaceutical industry reduce attrition rates?
Kola, I., & Landis, J. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1470 · Cited by 4,167
PHARMACOLOGY AND FUNCTIONS OF METABOTROPIC GLUTAMATE RECEPTORS
Conn, P. J., & Pin, J. (1997) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.37.1.205 · Cited by 3,083
The Ecology of Freshwater Phytoplankton.
Jones, R. I., & REYNOLDS, C. S. (1985) · Journal of Ecology · doi:10.2307/2260522 · Cited by 2,817
The mGluR theory of fragile X mental retardation
Bear, M. F., Huber, K. M., & Warren, S. T. (2004) · Trends in Neurosciences · doi:10.1016/j.tins.2004.04.009 · Cited by 1,580
G Protein-coupled Receptors
Ji, T. H., Grossmann, M., & Ji, I. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.28.17299 · Cited by 1,281
Maraviroc (UK-427,857), a Potent, Orally Bioavailable, and Selective Small-Molecule Inhibitor of Chemokine Receptor CCR5 with Broad-Spectrum Anti-Human Immunodeficiency Virus Type 1 Activity
Dorr, P. K., Westby, M., Dobbs, S., Griffin, P., Irvine, B., Macartney, M. J., Mori, J., Rickett, G., Smith‐Burchnell, C., Napier, C. M., et al. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.11.4721-4732.2005 · Cited by 1,154
Functional Selectivity and Classical Concepts of Quantitative Pharmacology
Urban, J. D., Clarke, W. P., von Zastrow, M., Nichols, D. E., Kobilka, B. K., Weinstein, H., Javitch, J. A., Roth, B. L., Christopoulos, A., Sexton, P. M., et al. (2006) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.106.104463 · Cited by 1,131
Self-citation
Operational models of pharmacological agonism
Black, J. W., & Leff, P. (1983) · Proceedings of the Royal Society B Biological Sciences · doi:10.1098/rspb.1983.0093 · Cited by 1,106
Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial
Patil, S. T., Zhang, L., Martenyi, F., Lowe, S. L., Jackson, K. A., Andreev, B. V., Avedisova, A. S., Bardenstein, L. M., Gurovich, I. Y., Morozova, M. A., et al. (2007) · Nature Medicine · doi:10.1038/nm1632 · Cited by 1,040
Reversal of Phencyclidine Effects by a Group II Metabotropic Glutamate Receptor Agonist in Rats
Moghaddam, B., & Adams, B. W. (1998) · Science · doi:10.1126/science.281.5381.1349 · Cited by 1,006

Flagged first, then by citations

Show all 139 references

Research works printed but not linked: 2

Swanson, C. J., Bures, M., Johnson, M. P., Linden, A. M., Monn, J. A. & Schoepp, D. D. Metabotropic glutamate receptors as novel targets for anxiety and stress disorders. Nature Rev. Drug Discov. 4, 131–144 (2005). · DOI · Paper page
Baez, M. et al. Molecular mapping of a subtype selective site for positive allosteric modulation of the mGlu2 receptor. Neuropharmacol. Abstr. 43, 274–275 (2002).

Sorted by citations

Items 301–400 of 1,000

G-Protein coupled receptors: structure and function in drug discovery
Odoemelam, C. S., Percival, B. C., Wallis, H., Chang, M., Ahmad, Z., Scholey, D. V., Burton, E. J., Williams, I. H., Kamerlin, S. C. L., & Wilson, P. (2020) · RSC Advances · doi:10.1039/d0ra08003a · Cited by 55
Allosteric modulation of GPCRs: From structural insights to in silico drug discovery
Persechino, M., Hedderich, J. B., Kolb, P., & Hilger, D. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108242 · Cited by 57
Structural determinants of allosteric antagonism at metabotropic glutamate receptor 2: mechanistic studies with new potent negative allosteric modulators
Lundström, L., Bissantz, C., Beck, J., Wettstein, J. G., Woltering, T. J., Wichmann, J., & Gatti, S. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01409.x · Cited by 53
Positive/Negative Allosteric Modulation Switching in an Umami Taste Receptor (T1R1/T1R3) by a Natural Flavor Compound, Methional
Toda, Y., Nakagita, T., Hirokawa, T., Yamashita, Y., Nakajima, A., Narukawa, M., Ishimaru, Y., Uchida, R., & Misaka, T. (2018) · Scientific Reports · doi:10.1038/s41598-018-30315-x · Cited by 54
Chemical lead optimization of a pan Gq mAChR M1, M3, M5 positive allosteric modulator (PAM) lead. Part II: Development of a potent and highly selective M1 PAM
Bridges, T. M., Kennedy, J. P., Noetzel, M. J., Breininger, M. L., Gentry, P. R., Conn, P. J., & Lindsley, C. W. (2010) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2010.01.109 · Cited by 54
Self-citation
Crystal structure of dopamine D1 receptor in complex with G protein and a non-catechol agonist
Sun, B., Feng, D., Chu, M. L.-H., Fish, I., Lovera, S., Sands, Z. A., Kelm, S., Valade, A., Wood, M. D., Ceska, T., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-23519-9 · Cited by 57
Use of Allosteric Targets in the Discovery of Safer Drugs
Grover, A. K. (2013) · Medical Principles and Practice · doi:10.1159/000350417 · Cited by 53
Allosteric modulation and functional selectivity of G protein-coupled receptors
Gao, Z., & Jacobson, K. A. (2012) · Drug Discovery Today Technologies · doi:10.1016/j.ddtec.2012.08.004 · Cited by 55
Mapping of Allosteric Druggable Sites in Activation‐Associated Conformers of the M2 Muscarinic Receptor
Miao, Y., Nichols, S. E., & McCammon, J. A. (2013) · Chemical Biology & Drug Design · doi:10.1111/cbdd.12233 · Cited by 53
Oral Sensing of Food Properties
Kohyama, K. (2014) · Journal of Texture Studies · doi:10.1111/jtxs.12099 · Cited by 52
Visualization and Quantitative Analysis of G Protein-Coupled Receptor−β-Arrestin Interaction in Single Cells and Specific Organs of Living Mice Using Split Luciferase Complementation
Takakura, H., Hattori, M., Takeuchi, M., & Ozawa, T. (2012) · ACS Chemical Biology · doi:10.1021/cb200360z · Cited by 52
Model for High-Throughput Screening of Multitarget Drugs in Chemical Neurosciences: Synthesis, Assay, and Theoretic Study of Rasagiline Carbamates
Alonso, N., Caamaño, O., Romero-Durán, F., Luan, F., Cordeiro, M. N. D. S., Yáñez, M., González‐Díaz, H., & Xerardo Garcia-mera, B. (2013) · ACS Chemical Neuroscience · doi:10.1021/cn400111n · Cited by 52
Enhancement of the surface expression of G protein-coupled receptors
Dunham, J. H., & Hall, R. A. (2009) · Trends in biotechnology · doi:10.1016/j.tibtech.2009.06.005 · Cited by 54
Chemical Switch of a Metabotropic Glutamate Receptor 2 Silent Allosteric Modulator into Dual Metabotropic Glutamate Receptor 2/3 Negative/Positive Allosteric Modulators
Schann, S., Mayer, S., Franchet, C., Frauli, M., Steinberg, E., Thomas, M., Baron, L., & Neuville, P. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm101069m · Cited by 52
Discovery, Synthesis, and Structure−Activity Relationship Development of a Series of N-(4-Acetamido)phenylpicolinamides as Positive Allosteric Modulators of Metabotropic Glutamate Receptor 4 (mGlu4) with CNS Exposure in Rats
Engers, D. W., Field, J. R., Le, U., Zhou, Y., Bolinger, J. D., Zamorano, R., Blobaum, A. L., Jones, C. K., Jadhav, S. B., Weaver, C. D., et al. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm101271s · Cited by 51
Self-citation
Diarylureas as Allosteric Modulators of the Cannabinoid CB1 Receptor: Structure–Activity Relationship Studies on 1-(4-Chlorophenyl)-3-{3-[6-(pyrrolidin-1-yl)pyridin-2-yl]phenyl}urea (PSNCBAM-1)
German, N., Decker, A. M., Gilmour, B. P., Gay, E. A., Wiley, J. L., Thomas, B. F., & Zhang, Y. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm501042u · Cited by 51
Allosteric Pathways in the PPARγ-RXRα nuclear receptor complex
Ricci, C. G., Silveira, R. L., Rivalta, I., Batista, V. S., & Skaf, M. S. (2016) · Scientific Reports · doi:10.1038/srep19940 · Cited by 51
Virtual Screening-Based Discovery and Mechanistic Characterization of the Acylthiourea MRT-10 Family as Smoothened Antagonists
Manetti, F., Faure, H., Roudaut, H., Gorojankina, T., Traiffort, É., Schoenfelder, A., Mann, A., Solinas, A., Taddei, M., & Ruat, M. (2010) · Molecular Pharmacology · doi:10.1124/mol.110.065102 · Cited by 50
Exploring the Allosteric Territory of Protein Function
Tee, W.-V., Tan, Z. W., Lee, K., Guarnera, E., & Berezovsky, I. N. (2021) · The Journal of Physical Chemistry B · doi:10.1021/acs.jpcb.1c00540 · Cited by 50
Quantitative Analysis Reveals Multiple Mechanisms of Allosteric Modulation of the mGlu5 Receptor in Rat Astroglia
Bradley, S. J., Langmead, C. J., Watson, J. M., & Challiss, R. A. J. (2011) · Molecular Pharmacology · doi:10.1124/mol.110.068882 · Cited by 49
Small Molecule Inhibitors of Regulators of G Protein Signaling (RGS) Proteins
Turner, E. M., Blazer, L. L., Neubig, R. R., & Husbands, S. M. (2011) · ACS Medicinal Chemistry Letters · doi:10.1021/ml200263y · Cited by 49
Neuroprotective and symptomatic effects of targeting group III mG lu receptors in neurodegenerative disease
Williams, C. J., & Dexter, D. T. (2013) · Journal of Neurochemistry · doi:10.1111/jnc.12608 · Cited by 48
Glutamatergic Targets for Enhancing Extinction Learning in Drug Addiction
Cleva, R. M., Gass, J. T., Widholm, J. J., & Olive, M. F. (2010) · Current Neuropharmacology · doi:10.2174/157015910793358169 · Cited by 51
Carassius gibelio in Greece: the dominant naturalised invader of freshwaters
Perdikaris, C., Ergolavou, A., Gouva, E., Nathanailides, C. I., Chantzaropoulos, A., & Paschos, I. (2011) · Reviews in Fish Biology and Fisheries · doi:10.1007/s11160-011-9216-8 · Cited by 48
Development of Artificial Cell Models Using Microfluidic Technology and Synthetic Biology
Kamiya, K. (2020) · Micromachines · doi:10.3390/mi11060559 · Cited by 49
Selective Photoswitchable Allosteric Agonist of a G Protein-Coupled Receptor
Donthamsetti, P., Konrad, D. B., Hetzler, B. E., Fu, Z., Trauner, D. H., & Isacoff, E. Y. (2021) · Journal of the American Chemical Society · doi:10.1021/jacs.1c02586 · Cited by 48
The antipsychotic‐like effects of positive allosteric modulators of metabotropic glutamate m G lu4 receptors in rodents
Sławińska, A., Wierońska, J. M., Stachowicz, K., Marciniak, M., Łasoń, M., Gruca, P., Papp, M., Kusek, M., Tokarski, K., Doller, D., et al. (2013) · British Journal of Pharmacology · doi:10.1111/bph.12254 · Cited by 48
Emerging opportunities for allosteric modulation of G-protein coupled receptors
Wang, C.-I. A., & Lewis, R. J. (2012) · Biochemical Pharmacology · doi:10.1016/j.bcp.2012.09.001 · Cited by 47
Thermodynamics of allostery paves a way to allosteric drugs
Berezovsky, I. N. (2013) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2013.01.024 · Cited by 47
Disease-Modifying Effects of M1 Muscarinic Acetylcholine Receptor Activation in an Alzheimer’s Disease Mouse Model
Lebois, E. P., Schroeder, J. P., Esparza, T. J., Bridges, T. M., Lindsley, C. W., Conn, P. J., Brody, D. L., Daniels, J. S., & Levey, A. I. (2017) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.6b00278 · Cited by 45
Self-citation
Neuropharmacological Insight from Allosteric Modulation of mGlu Receptors
Stansley, B. J., & Conn, P. J. (2019) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2019.02.006 · Cited by 47
Biased M1-muscarinic-receptor-mutant mice inform the design of next-generation drugs
Bradley, S. J., Molloy, C., Valuskova, P., Dwomoh, L., Scarpa, M., Rossi, M., Finlayson, L., Svensson, K. A., Chernet, E., Barth, V., et al. (2020) · Nature Chemical Biology · doi:10.1038/s41589-019-0453-9 · Cited by 47
Self-citation
Effects of Selective Activation of M1 and M4 Muscarinic Receptors on Object Recognition Memory Performance in Rats
Galloway, C. R., Lebois, E. P., Shagarabi, S. L., Hernandez, N. A., & Manns, J. R. (2014) · Pharmacology · doi:10.1159/000357682 · Cited by 46
An orally bioavailable positive allosteric modulator of the mGlu4 receptor with efficacy in an animal model of motor dysfunction
East, S. P., Bamford, S. J., Dietz, M. G. A., Eickmeier, C., Flegg, A., Ferger, B., Gemkow, M. J., Heilker, R., Hengerer, B., Kotey, A., et al. (2010) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2010.06.078 · Cited by 46
The hippocampo-prefrontal pathway: a possible therapeutic target for negative and cognitive symptoms of schizophrenia
Ghoshal, A., & Conn, P. J. (2015) · Future Neurology · doi:10.2217/fnl.14.63 · Cited by 50
An Allosteric Potentiator of the Dopamine D1 Receptor Increases Locomotor Activity in Human D1 Knock-In Mice without Causing Stereotypy or Tachyphylaxis
Svensson, K. A., Heinz, B. A., Schaus, J. M., Beck, J. P., Hao, J., Krushinski, J. H., Reinhard, M. R., Cohen, M. P., Hellman, S. L., Getman, B. G., et al. (2016) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.116.236372 · Cited by 47
The δ‐opioid receptor positive allosteric modulator BMS 986187 is a G‐protein‐biased allosteric agonist
Stanczyk, M. A., Livingston, K. E., Chang, L. C., Weinberg, Z. Y., Puthenveedu, M. A., & Traynor, J. R. (2019) · British Journal of Pharmacology · doi:10.1111/bph.14602 · Cited by 46
Allosteric modulation of Class C GPCRs: a novel approach for the treatment of CNS disorders
Engers, D. W., & Lindsley, C. W. (2013) · Drug Discovery Today: Technologies · doi:10.1016/j.ddtec.2012.10.007 · Cited by 45
Self-citation
Discovery of molecular switches within the ADX-47273 mGlu5 PAM scaffold that modulate modes of pharmacology to afford potent mGlu5 NAMs, PAMs and partial antagonists
Lamb, J. P., Engers, D. W., Niswender, C. M., Rodriguez, A. L., Venable, D. F., Conn, P. J., & Lindsley, C. W. (2010) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2010.11.119 · Cited by 45
Self-citation
Structural Systems Pharmacology: The Role of 3D Structures in Next-Generation Drug Development
Duran‐Frigola, M., Mosca, R., & Aloy, P. (2013) · Chemistry & Biology · doi:10.1016/j.chembiol.2013.03.004 · Cited by 44
A2A adenosine receptor ligand binding and signalling is allosterically modulated by adenosine deaminase
Gracia, E., Pérez‐Capote, K., Moreno, E., Barkešová, J., Mallol, J., Lluís, C., Franco, R., Cortés, A., Casadó, V., & Canela, E. I. (2011) · Biochemical Journal · doi:10.1042/bj20101749 · Cited by 45
ML314: A Biased Neurotensin Receptor Ligand for Methamphetamine Abuse
Barak, L. S., Bai, Y., Peterson, S. M., Evron, T., Urs, N. M., Peddibhotla, S., Hedrick, M. P., Hershberger, P., Maloney, P., Chung, T. D. Y., et al. (2016) · ACS Chemical Biology · doi:10.1021/acschembio.6b00291 · Cited by 44
Molecular Switches of Allosteric Modulation of the Metabotropic Glutamate 2 Receptor
Pérez‐Benito, L., Doornbos, M. L. J., Cordomí, A., Peeters, L., Lavreysen, H., Pardo, L., & Tresadern, G. (2017) · Structure · doi:10.1016/j.str.2017.05.021 · Cited by 45
Muscarinic M5 receptors modulate ethanol seeking in rats
Berizzi, A. E., Perry, C. J., Shackleford, D. M., Lindsley, C. W., Jones, C. K., Chen, N. A., Sexton, P. M., Christopoulos, A., Langmead, C. J., & Lawrence, A. J. (2018) · Neuropsychopharmacology · doi:10.1038/s41386-017-0007-3 · Cited by 42
Self-citation
Discovery of 2‐(2‐Benzoxazoyl amino)‐4‐Aryl‐5‐Cyanopyrimidine as Negative Allosteric Modulators (NAMs) of Metabotropic Glutamate Receptor 5 (mGlu5): From an Artificial Neural Network Virtual Screen to an In Vivo Tool Compound
Mueller, R., Dawson, E. S., Meiler, J., Rodriguez, A. L., Chauder, B. A., Bates, B. S., Felts, A. S., Lamb, J. P., Menon, U. N., Jadhav, S. B., et al. (2012) · ChemMedChem · doi:10.1002/cmdc.201100510 · Cited by 45
Self-citation
Coumarin-3-carboxylic acid derivatives as potentiators and inhibitors of recombinant and native N-methyl-d-aspartate receptors
Irvine, M. W., Costa, B. M., Volianskis, A., Fang, G., Ceolin, L., Collingridge, G. L., Monaghan, D. T., & Jane, D. E. (2012) · Neurochemistry International · doi:10.1016/j.neuint.2011.12.020 · Cited by 46
Novel pharmacological targets for GABAergic dysfunction in ADHD
Ferranti, A. S., Luessen, D. J., & Niswender, C. M. (2024) · Neuropharmacology · doi:10.1016/j.neuropharm.2024.109897 · Cited by 48
Cannabinoid receptor antagonists AM251 and AM630 activate TRPA1 in sensory neurons
Patil, M. J., Patwardhan, A. M., Salas, M. M., Hargreaves, K., & Akopian, A. N. (2011) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.05.024 · Cited by 44
Reduction of excessive alcohol drinking by a novel GABAB receptor positive allosteric modulator ADX71441 in mice
Hwa, L. S., Kalinichev, M., Haddouk, H., Poli, S. M., & Miczek, K. A. (2013) · Psychopharmacology · doi:10.1007/s00213-013-3245-z · Cited by 44
Delineating the Mode of Action of Adenosine A1 Receptor Allosteric Modulators
Valant, C., Aurelio, L., Urmaliya, V., White, P. J., Scammells, P. J., Sexton, P. M., & Christopoulos, A. (2010) · Molecular Pharmacology · doi:10.1124/mol.110.064568 · Cited by 44
Self-citation
Allosteric communication pipelines in G-protein-coupled receptors
Vaidehi, N., & Bhattacharya, S. (2016) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2016.07.010 · Cited by 44
Photochromic Dopamine Receptor Ligands Based on Dithienylethenes and Fulgides
Lachmann, D., Studte, C., Männel, B., Hübner, H., Gmeiner, P., & König, B. (2017) · Chemistry - A European Journal · doi:10.1002/chem.201702147 · Cited by 44
Metabotropic Glutamate Receptors as Targets for Analgesia: Antagonism, Activation, and Allosteric Modulation
Montana, M. C., & Gereau, R. W. (2011) · Current Pharmaceutical Biotechnology · doi:10.2174/138920111798357438 · Cited by 45
Molecular mechanism of positive allosteric modulation of the metabotropic glutamate receptor 2 by JNJ‐46281222
Doornbos, M. L. J., Pérez‐Benito, L., Tresadern, G., Mulder‐Krieger, T., Biesmans, I., Trabanco, A. A., Cid, J. M., Lavreysen, H., IJzerman, A. P., & Heitman, L. H. (2015) · British Journal of Pharmacology · doi:10.1111/bph.13390 · Cited by 43
Prediction of Orthosteric and Allosteric Regulations on Cannabinoid Receptors Using Supervised Machine Learning Classifiers
Bian, Y., Jing, Y., Wang, L., Ma, S., Jun, J. J., & Xie, X. (2019) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.9b00182 · Cited by 43
Synthesis and Structure–Activity Relationships of Allosteric Potentiators of the M4 Muscarinic Acetylcholine Receptor
Kennedy, J. P., Bridges, T. M., Gentry, P. R., Brogan, J. T., Kane, A. S., Jones, C. K., Brady, A. E., Shirey-Rice, J. K., Conn, P. J., & Lindsley, C. W. (2009) · ChemMedChem · doi:10.1002/cmdc.200900231 · Cited by 43
Self-citation
Regulator of G-Protein Signaling 18 Controls Both Platelet Generation and Function
Delesque-Touchard, N., Pendaries, C., Volle‐Challier, C., Millet, L., Salel, V., Hervé, C., Pflieger, A.-M., Berthou-Soulié, L., Prades, C., Sorg, T., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0113215 · Cited by 42
Discovery of D1 Dopamine Receptor Positive Allosteric Modulators: Characterization of Pharmacology and Identification of Residues that Regulate Species Selectivity
Lewis, M. A., Hunihan, L. W., Watson, J., Gentles, R. G., Hu, S., Huang, Y., Bronson, J. J., Macor, J. E., Beno, B. R., Ferrante, M. A., et al. (2015) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.115.224071 · Cited by 42
Ultrastructural localization and function of dopamine D1‐like receptors in the substantia nigra pars reticulata and the internal segment of the globus pallidus of parkinsonian monkeys
Kliem, M. A., Paré, J., Khan, Z. U., Wichmann, T., & Smith, Y. (2010) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2010.07109.x · Cited by 42
The discovery of novel calcium sensing receptor negative allosteric modulators
Balan, G., Bauman, J. N., Bhattacharya, S. K., Castrodad, M., Healy, D. R., Herr, M., Humphries, P. S., Jennings, S. M., Kalgutkar, A. S. S., Kapinos, B., et al. (2009) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2009.04.044 · Cited by 42
Recent Advances in the Discovery of Nicotinic Acetylcholine Receptor Allosteric Modulators
Manetti, D., Dei, S., Arias, H. R., Braconi, L., Gabellini, A., Teodori, E., & Romanelli, M. N. (2023) · Molecules · doi:10.3390/molecules28031270 · Cited by 42
Partial mGlu5 Negative Allosteric Modulators Attenuate Cocaine-Mediated Behaviors and Lack Psychotomimetic-Like Effects
Gould, R. W., Amato, R. J., Bubser, M., Joffe, M. E., Nedelcovych, M. T., Thompson, A. D., Nickols, H. H., Yuh, J. P., Zhan, X., Felts, A. S., et al. (2015) · Neuropsychopharmacology · doi:10.1038/npp.2015.265 · Cited by 41
Self-citation
Transcriptome Sequencing of the Anterior Cingulate in Bipolar Disorder: Dysregulation of G Protein-Coupled Receptors
Cruceanu, C., Tan, P. P. C., Rogić, S., López, J. P., Torres-Platas, S. G., Gigek, C. O., Alda, M., Rouleau, G. A., Pavlidis, P., & Turecki, G. (2015) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2015.14101279 · Cited by 43
Development of a high throughput screen for allosteric modulators of melanocortin-4 receptor signaling using a real time cAMP assay
Pantel, J., Williams, S. Y., Mi, D., Sebag, J. A., Corbin, J. D., Weaver, C. D., & Cone, R. D. (2011) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2011.01.031 · Cited by 41
Targeting Selective Activation of M1 for the Treatment of Alzheimer’s Disease: Further Chemical Optimization and Pharmacological Characterization of the M1 Positive Allosteric Modulator ML169
Tarr, J. C., Turlington, M., Reid, P. R., Utley, T. J., Sheffler, D. J., Cho, H. P., Klar, R., Pancani, T., Klein, M. T., Bridges, T. M., et al. (2012) · ACS Chemical Neuroscience · doi:10.1021/cn300068s · Cited by 41
Self-citation
Structure–Activity Study ofN-((trans)-4-(2-(7-Cyano-3,4-dihydroisoquinolin-2(1H)-yl)ethyl)cyclohexyl)-1H-indole-2-carboxamide (SB269652), a Bitopic Ligand That Acts as a Negative Allosteric Modulator of the Dopamine D2Receptor
Shonberg, J., Draper-Joyce, C. J., Mistry, S. N., Christopoulos, A., Scammells, P. J., Lane, J. R., & Capuano, B. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00581 · Cited by 41
Self-citation
A new paradigm for navigating compound property related drug attrition
Barton, P., & Riley, R. J. (2015) · Drug Discovery Today · doi:10.1016/j.drudis.2015.09.010 · Cited by 41
MK-7622: A First-in-Class M 1 Positive Allosteric Modulator Development Candidate
Beshore, D. C., Marco, C. N. D., Chang, R. K., Greshock, T. J., Ma, L., Wittmann, M., Seager, M. A., Koeplinger, K. A., Thompson, C. D., Fuerst, J., et al. (2018) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.8b00095 · Cited by 41
Deep Learning Dynamic Allostery of G-Protein-Coupled Receptors
Do, H. N., Wang, J., & Miao, Y. (2023) · JACS Au · doi:10.1021/jacsau.3c00503 · Cited by 40
Structure–activity relationships of substituted 1H-indole-2-carboxamides as CB1 receptor allosteric modulators
Nguyen, T., German, N., Decker, A. M., Li, J., Wiley, J. L., Thomas, B. F., Kenakin, T., & Zhang, Y. (2015) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2015.02.058 · Cited by 40
Synthesis and SAR of centrally active mGlu5 positive allosteric modulators based on an aryl acetylenic bicyclic lactam scaffold
Williams, R. D., Manka, J. T., Rodriguez, A. L., Vinson, P. N., Niswender, C. M., Weaver, C. D., Jones, C. K., Conn, P. J., Lindsley, C. W., & Stauffer, S. R. (2011) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2011.01.044 · Cited by 40
Self-citation
Development of a novel, CNS-penetrant, metabotropic glutamate receptor 3 (mGlu3) NAM probe (ML289) derived from a closely related mGlu5 PAM
Sheffler, D. J., Wenthur, C. J., Bruner, J. A., Carrington, S. J. S., Vinson, P. N., Gogi, K. K., Blobaum, A. L., Morrison, R. D., Vamos, M., Cosford, N. D. P., et al. (2012) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2012.04.112 · Cited by 40
Self-citation
A Positive Allosteric Modulator of the Serotonin 5-HT2CReceptor for Obesity
Garcı́a-Cárceles, J., Decara, J. M., Vázquez‐Villa, H., Rodríguez, R., Codesido, E., Cruces, J., Brea, J. M., Loza, M. I., Alén, F., Botta, J. A., et al. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00994 · Cited by 40
Activation mechanism of the μ-opioid receptor by an allosteric modulator
Kaneko, S., Imai, S., Asao, N., Kofuku, Y., Ueda, T., & Shimada, I. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2121918119 · Cited by 41
Toward understanding the molecular basis for chemical allosteric modulator design
Wang, Q., Zheng, M., Huang, Z., Liu, X., Zhou, H., Chen, Y., Shi, T., & Zhang, J. (2012) · Journal of Molecular Graphics and Modelling · doi:10.1016/j.jmgm.2012.07.006 · Cited by 40
Xanomeline displays concomitant orthosteric and allosteric binding modes at the M4 mAChR
Burger, W. A. C., Pham, V., Vuckovic, Z., Powers, A. S., Mobbs, J. I., Laloudakis, Y. D., Glukhova, A., Wootten, D. L., Tobin, A. B., Sexton, P. M., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-41199-5 · Cited by 39
Self-citation
Structural and dynamic insights into the activation of the μ-opioid receptor by an allosteric modulator
Kaneko, S., Imai, S., Uchikubo‐Kamo, T., Hisano, T., Asao, N., Shirouzu, M., & Shimada, I. (2024) · Nature Communications · doi:10.1038/s41467-024-47792-6 · Cited by 39
Allosteric Modulation of Purine and Pyrimidine Receptors
Jacobson, K. A., Gao, Z., Göblyös, A., & IJzerman, A. P. (2011) · Advances in pharmacology · doi:10.1016/b978-0-12-385526-8.00007-2 · Cited by 39
Effects of the Allosteric Antagonist 1-(4-Chlorophenyl)-3-[3-(6-pyrrolidin-1-ylpyridin-2-yl)phenyl]urea (PSNCBAM-1) on CB1 Receptor Modulation in the Cerebellum
Wang, X., Horswill, J. G., Whalley, B. J., & Stephens, G. J. (2010) · Molecular Pharmacology · doi:10.1124/mol.110.068197 · Cited by 39
Mapping Cannabinoid 1 Receptor Allosteric Site(s): Critical Molecular Determinant and Signaling Profile of GAT100, a Novel, Potent, and Irreversibly Binding Probe
Laprairie, R. B., Kulkarni, A., Kulkarni, P. M., Hurst, D. P., Lynch, D. L., Reggio, P. H., Janero, D. R., Pertwee, R. G., Stevenson, L., Kelly, M. E. M., et al. (2016) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.6b00041 · Cited by 40
The function and allosteric control of the human sweet taste receptor
Servant, G., Kenakin, T., Zhang, L., Williams, M., & Servant, N. B. (2020) · Advances in pharmacology · doi:10.1016/bs.apha.2020.01.002 · Cited by 39
Biased signaling in naturally occurring mutations of G protein-coupled receptors associated with diverse human diseases
Yang, L.-K., Hou, Z.-S., & Tao, Y. (2020) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2020.165973 · Cited by 40
Quantification of Allosteric Interactions at G Protein–Coupled Receptors Using Radioligand Binding Assays
Leach, K., Sexton, P. M., & Christopoulos, A. (2011) · Current Protocols in Pharmacology · doi:10.1002/0471141755.ph0122s52 · Cited by 39
Self-citation
Synthesis and SAR of a novel positive allosteric modulator (PAM) of the metabotropic glutamate receptor 4 (mGluR4)
Williams, R. D., Johnson, K. A., Gentry, P. R., Niswender, C. M., Weaver, C. D., Conn, P. J., Lindsley, C. W., & Hopkins, C. R. (2009) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2009.07.072 · Cited by 39
Self-citation
Allosteric Modulators of Metabotropic Glutamate Receptors as Novel Therapeutics for Neuropsychiatric Disease
Luessen, D. J., & Conn, P. J. (2022) · Pharmacological Reviews · doi:10.1124/pharmrev.121.000540 · Cited by 42
Troubleshooting and deconvoluting label-free cell phenotypic assays in drug discovery
Ye, F. (2013) · Journal of Pharmacological and Toxicological Methods · doi:10.1016/j.vascn.2013.01.004 · Cited by 38
Development of a highly selective, orally bioavailable and CNS penetrant M1 agonist derived from the MLPCN probe ML071
Lebois, E. P., Digby, G. J., Sheffler, D. J., Melancon, B. J., Tarr, J. C., Cho, H. P., Miller, N., Morrison, R. D., Bridges, T. M., Xiang, Z., et al. (2011) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2011.08.084 · Cited by 38
Self-citation
Recent Progress on the Identification of Metabotropic Glutamate 4 Receptor Ligands and Their Potential Utility as CNS Therapeutics
Robichaud, A. J., Engers, D. W., Lindsley, C. W., & Hopkins, C. R. (2011) · ACS Chemical Neuroscience · doi:10.1021/cn200043e · Cited by 38
Self-citation
Remarkable similarities between the hemichordate (Saccoglossus kowalevskii) and vertebrate GPCR repertoire
Krishnan, A., Almén, M. S., Fredriksson, R., & Schiöth, H. B. (2013) · Gene · doi:10.1016/j.gene.2013.05.005 · Cited by 36
A Molecular Mechanism for Sequential Activation of a G Protein-Coupled Receptor
Grundmann, M., Tikhonova, I. G., Hudson, B. D., Smith, N. J., Mohr, K., Ulven, T., Milligan, G., Kenakin, T., & Kostenis, E. (2016) · Cell chemical biology · doi:10.1016/j.chembiol.2016.02.014 · Cited by 37
Potent Prearranged Positive Allosteric Modulators of the Glucagon‐like Peptide‐1 Receptor
Jones, B. J., Scopelliti, R., Tomás, A., Bloom, S. R., Hodson, D. J., & Broichhagen, J. (2017) · ChemistryOpen · doi:10.1002/open.201700062 · Cited by 38
Allosteric modulators of cannabinoid receptor 1: developing compounds for improved specificity
Dopart, R., Lu, D., Lichtman, A. H., & Kendall, D. A. (2018) · Drug Metabolism Reviews · doi:10.1080/03602532.2018.1428342 · Cited by 38
Design, Synthesis, and Characterization of 4-Undecylpiperidine-2-carboxamides as Positive Allosteric Modulators of the Serotonin (5-HT) 5-HT2CReceptor
Wild, C., Miszkiel, J., Wold, E. A., Soto, C. A., Ding, C., Hartley, R., White, M. A., Anastasio, N. C., Cunningham, K. A., & Zhou, J. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00401 · Cited by 38
The Muscarinic Acetylcholine Receptor M 5 : Therapeutic Implications and Allosteric Modulation
Bender, A. M., Garrison, A. T., & Lindsley, C. W. (2018) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.8b00481 · Cited by 38
Self-citation
Allosteric Binding Site and Activation Mechanism of Class C G-Protein Coupled Receptors: Metabotropic Glutamate Receptor Family
Feng, Z., Ma, S., Hu, G., & Xie, X. (2015) · The AAPS Journal · doi:10.1208/s12248-015-9742-8 · Cited by 38
A novel fast mechanism for GPCR-mediated signal transduction—control of neurotransmitter release
Kupchik, Y. M., Barchad-Avitzur, O., Wess, J., Ben-Chaim, Y., Parnas, I., & Parnas, H. (2011) · The Journal of Cell Biology · doi:10.1083/jcb.201007053 · Cited by 37
Allosteric modulation of G protein-coupled receptors as a novel therapeutic strategy in neuropathic pain
Zhu, C., Lan, X., Wei, Z., Yu, J., & Zhang, J. (2023) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2023.07.020 · Cited by 39
Phosphodiesterase 4 inhibitors for the treatment of chronic obstructive pulmonary disease: a review of current and developing drugs
Mulhall, A. M., Droege, C. A., Ernst, N. E., Panos, R. J., & Zafar, M. A. (2015) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2015.1094054 · Cited by 37
On the interaction mechanisms of a p53 peptide and nutlin with the MDM2 and MDMX proteins: A Brownian dynamics study
ElSawy, K. M., Verma, C. S., Joseph, T. L., Lane, D. P., Twarock, R., & Caves, L. S. D. (2013) · Cell Cycle · doi:10.4161/cc.23511 · Cited by 37
Allosteric Modulators Targeting Cannabinoid cb1 and cb2 Receptors: Implications for Drug Discovery
Gado, F., Meini, S., Bertini, S., Digiacomo, M., Macchia, M., & Manera, C. (2019) · Future Medicinal Chemistry · doi:10.4155/fmc-2019-0005 · Cited by 42

Authors: Jeffrey Conn, P., Christopoulos, A., & Lindsley, C. W.
Affiliations: Monash University (AU)
Vanderbilt University (US)
ORCID: Christopoulos, Arthur
Lindsley, Craig W.
Venue: Nature Reviews Drug Discovery
Publisher: Springer Science and Business Media LLC
Published: 2009-01
Volume: 8
Issue: 1
Pages: 41-54
ISSN: 1474-1776 (ISSN-L)
1474-1784
DOI: 10.1038/nrd2760
PMC: PMC2907734
OpenAlex: W2003736358
Cited by: 1,063
References: 139
Citations by year: 2026: 30 · 2025: 46 · 2024: 37 · 2023: 25 · 2022: 48 · 2021: 51 · 2020: 44 · 2019: 58 · 2018: 57 · 2017: 68 · 2016: 64 · 2015: 67 · 2014: 69 · 2013: 80 · 2012: 75
FWCI: 6.60
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Licence: www.springer.com/tdm (tdm)
Locations: Nature Reviews Drug Discovery (publishedVersion)
PubMed (publishedVersion)
Europe PMC (PubMed Central) (acceptedVersion)
PubMed Central (acceptedVersion)
Funders: National Institute of Mental Health (R01MH073676, R01MH074953, R01MH062646)
National Institute on Drug Abuse (R01DA023926)
National Institute of Neurological Disorders and Stroke (R01NS031373)
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Receptor Mechanisms and Signaling
Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
Keywords: G protein-coupled receptors, allosteric modulators, allosteric site, orthosteric ligands, mental illness, neurological disorders, CNS drug discovery, receptor selectivity, novel therapeutic agents
MeSH terms: Allosteric Regulation, Animals, Central Nervous System Diseases, Drug Evaluation, Preclinical, Humans, Ligands, Drug Design, Receptors, G-Protein-Coupled

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Allosteric modulators of GPCRs: a novel approach for the treatment of CNS disorders

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks